Novo Nordisk’s stock tumbles as doubts persist about Ozempic maker’s strategy
Source: www.marketwatch.com ·
Section: business-tech ·
Bias: Center-Left
· Published: Mon, 21 Sep 2026 20:23:00 GMT
The drugmaker, best known for developing weight-loss and diabetes drugs, failed to excite investors hoping for a turnaround.
Read the full article at www.marketwatch.com →
The same story across the political spectrum (1 sources)
← Back to FlashTopics.com